詳細
Imatinib was developed by Novartis. It was first approved for marketing by the US Food and Drug Administration (FDA) on May 10, 2001, and then approved for marketing by the European Medicines Agency (EMA) on November 7, 2001. On March 9, it was approved for marketing by the Japan Pharmaceuticals and Medical Devices Agency (PMDA). It is marketed in the United States by Novartis under the trade name Gleevec.
https://www.medixocentre.com/gleevec-imatinib-cost
関連製品
